Northwestern Mutual Wealth Management Co. Makes New Investment in Stryker Corporation $SYK

Key Points

• Northwestern Mutual Wealth Management acquired 45,200 Stryker shares worth approximately $14.2 million, while institutional investors overall own about 77.1% of the company.
• Stryker reported stronger-than-expected quarterly results, with EPS of $3.69 and revenue of $6.59 billion, up 9.4% year over year. The company maintained fiscal 2026 EPS guidance of $14.95–$15.10.
• Analysts remain broadly bullish, with a “Moderate Buy” consensus and an average price target of $386.28, though several firms recently cut targets and insiders have sold substantial shares.

Northwestern Mutual Wealth Management Co. bought a new stake in shares of Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 45,200 shares of the medical technology company's stock, valued at approximately $14,231,000.

A number of other large investors also recently made changes to their positions in SYK. Sankala Group LLC acquired a new stake in shares of Stryker during the fourth quarter worth approximately $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker in the 4th quarter valued at approximately $26,000. United Financial Planning Group LLC purchased a new stake in Stryker in the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker during the 4th quarter valued at $27,000. Finally, Gables Capital Management Inc. acquired a new stake in shares of Stryker during the 2nd quarter valued at $25,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Price Performance

NYSE SYK opened at $329.86 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The stock's 50-day moving average is $326.99 and its two-hundred day moving average is $332.64. The firm has a market cap of $126.52 billion, a P/E ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm's revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker's dividend payout ratio is presently 36.48%.

Insiders Place Their Bets

In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 665,370 shares of company stock valued at $216,238,501 over the last 90 days. 4.60% of the stock is currently owned by company insiders.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Raymond James Financial set a $370.00 target price on Stryker in a research note on Friday, July 31st. BTIG Research dropped their target price on Stryker from $371.00 to $358.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. Citizens Jmp cut their price target on Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research note on Monday, August 3rd. Finally, BMO Capital Markets started coverage on Stryker in a report on Wednesday, July 8th. They set an "outperform" rating and a $369.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source